Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4.
Arnott
I D
ID
Shand
A
A
Ghosh
S
S
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003176:Complement C3; D003181:Complement C4; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D011446:Prospective Studies
D000911:Antibodies, Monoclonal; D003176:Complement C3; D003181:Complement C4; D005765:Gastrointestinal Agents; D000069285:Infliximab